[PCN155] A Cost-Effectiveness Analysis Of A Genomic Test Compared To Standard Of Care In Breast Cancer Patients In France

[PCN155] A Cost-Effectiveness Analysis Of A Genomic Test Compared To Standard Of Care In Breast Cancer Patients In France

2015 Value in Health

Dorey, J. | Disset, A. | Elmoctar Neine, M. | Plun-Favreau, J. | Toumi, M. | Volume: 18, Issue: 7, Pages: A457,

The 21-gene Breast Cancer Test (Oncotype DX®) is a validated diagnostic test that predicts the likelihood of adjuvant chemotherapy benefit and breast cancer recurrence in selected patients with early-stage breast cancer. A previous cost-effectiveness analysis of this test versus standard French clinical practice was published in 2012. Since then, docetaxel is no longer reimbursed on top of the diagnosis related groups (DRGs). The objective of this study was to update the cost-effectiveness analysis considering this change.

https://www.doi.org/10.1016/j.jval.2015.09.1172